An updated analysis of the phase 3 KEYNOTE-564 study demonstrates that adjuvant pembrolizumab continued to show a consistent and clinically meaningful improvement in disease-free survival (DFS) compared with placebo in patients with renal cell carcinoma (RCC) at high risk for recurrence.
With 30 months of follow-up, the 24-month DFS rate in the intent-to-treat population was 78.3% in patients randomized to pembrolizumab versus 67.3% in those assigned to placebo, representing a hazard ratio
JUNE 10, 2022